BioNote（A377740）株式概要バイオノート社は、韓国で動物用体外診断用医薬品を製造・販売している。 詳細A377740 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金1/6リスク分析過去5年間で収益は年間64.6%減少しました。 不安定な配当実績 すべてのリスクチェックを見るA377740 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW489,735 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG489,735 investors already sharing narrativesYour Fair Value₩Current Price₩4.70k4.6k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-50b929b2016201920222025202620282031Revenue ₩3.0bEarnings ₩536.0mAdvancedSet Fair ValueView all narrativesBioNote, Inc. 競合他社Medy-ToxSymbol: KOSDAQ:A086900Market cap: ₩466.7bGCSymbol: KOSE:A005250Market cap: ₩438.9bOnconic TherapeuticsSymbol: KOSDAQ:A476060Market cap: ₩658.4bHEM PharmaSymbol: KOSDAQ:A376270Market cap: ₩287.4b価格と性能株価の高値、安値、推移の概要BioNote過去の株価現在の株価₩4,700.0052週高値₩6,320.0052週安値₩4,240.00ベータ0.641ヶ月の変化1.51%3ヶ月変化-10.98%1年変化-11.32%3年間の変化-17.40%5年間の変化n/aIPOからの変化-55.87%最新ニュースBuy Or Sell Opportunity • May 13Now 23% overvaluedOver the last 90 days, the stock has fallen 14% to ₩5,010. The fair value is estimated to be ₩4,067, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Apr 10Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to ₩4,970. The fair value is estimated to be ₩4,134, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,110, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past three years.Declared Dividend • Feb 28Dividend of ₩229 announcedShareholders will receive a dividend of ₩229. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but not adequately covered by cash flows (99% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 81% to shift the payout ratio to a potentially unsustainable range, which is more than the 27% EPS decline seen over the last 5 years.お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2026BioNote, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Koreaお知らせ • Feb 21BioNote, Inc. to Report Fiscal Year 2025 Results on Feb 25, 2026BioNote, Inc. announced that they will report fiscal year 2025 results on Feb 25, 2026最新情報をもっと見るRecent updatesBuy Or Sell Opportunity • May 13Now 23% overvaluedOver the last 90 days, the stock has fallen 14% to ₩5,010. The fair value is estimated to be ₩4,067, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Apr 10Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to ₩4,970. The fair value is estimated to be ₩4,134, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,110, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past three years.Declared Dividend • Feb 28Dividend of ₩229 announcedShareholders will receive a dividend of ₩229. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but not adequately covered by cash flows (99% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 81% to shift the payout ratio to a potentially unsustainable range, which is more than the 27% EPS decline seen over the last 5 years.お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2026BioNote, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Koreaお知らせ • Feb 21BioNote, Inc. to Report Fiscal Year 2025 Results on Feb 25, 2026BioNote, Inc. announced that they will report fiscal year 2025 results on Feb 25, 2026分析記事 • Nov 25BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings SuggestBioNote, Inc. ( KRX:377740 ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...お知らせ • Oct 28BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450).BioNote, Inc. (KOSE:A377740) signed a stock transfer agreement to acquire an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) for KRW 21.9 billion on September 26, 2025. A cash consideration of KRW 21.88 billion valued at KRW 8532 per share will be paid by BioNote, Inc. As part of consideration, KRW 21.88 billion is paid towards common equity of CTCBIO Inc. The expected completion of the transaction is December 24, 2025. BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) on October 27, 2025. On completion, BioNote, Inc. and PharmaResearch Co., Ltd. will own 23.04% and 10.61% stake respectively in CTCBIO Inc.Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: ₩834 (vs ₩66.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩834 (up from ₩66.00 in 2Q 2024). Revenue: ₩32.4b (up 23% from 2Q 2024). Net income: ₩84.5b (up ₩77.8b from 2Q 2024).お知らせ • Jul 08BioNote, Inc. (KOSE:A377740) announces an Equity Buyback for KRW 5,000 million worth of its shares.BioNote, Inc. (KOSE:A377740) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with NH Investment & Securities. The purpose of the program is to stabilize stock price and improve shareholder value. The program will expire on January 27, 2026. As of July 7, 2025, the company had 694,802 shares in treasury within scope available for dividend and no shares under other acquisitions.分析記事 • May 26BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings SuggestEven though BioNote, Inc.'s ( KRX:377740 ) recent earnings release was robust, the market didn't seem to notice. Our...Declared Dividend • Feb 27Dividend of ₩200 announcedDividend of ₩200 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 10% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2025BioNote, Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Koreaお知らせ • Feb 26BioNote, Inc. announces Annual dividendBioNote, Inc. announced Annual dividend of KRW 200.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.分析記事 • Nov 24BioNote's (KRX:377740) Strong Earnings Are Of Good QualityDespite posting some strong earnings, the market for BioNote, Inc.'s ( KRX:377740 ) stock hasn't moved much. Our...New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (117% cash payout ratio). Share price has been volatile over the past 3 months (9.1% average weekly change). Large one-off items impacting financial results.分析記事 • Aug 16BioNote, Inc.'s (KRX:377740) 38% Price Boost Is Out Of Tune With EarningsThe BioNote, Inc. ( KRX:377740 ) share price has done very well over the last month, posting an excellent gain of 38...Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩5,740, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 18% over the past year.お知らせ • Aug 02BioNote, Inc. (KOSE:A377740) announces an Equity Buyback for KRW 10,000 million worth of its shares.BioNote, Inc. (KOSE:A377740) announces a share repurchase program. Under the program, the company will repurchase up to KRW 10,000 million worth of its shares, pursuant to a contract with NH Investment & Securities. The purpose of the program is to stabilize stock price and improve shareholder value. The program will expire on February 3, 2025. As of August 1, 2024, the company had no shares in treasury within scope available for dividend and under other acquisitions.分析記事 • May 25There May Be Some Bright Spots In BioNote's (KRX:377740) EarningsThe market for BioNote, Inc.'s ( KRX:377740 ) shares didn't move much after it posted weak earnings recently. We did...Upcoming Dividend • Mar 21Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 17 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 11%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.5%).Buy Or Sell Opportunity • Mar 07Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩4,355. The fair value is estimated to be ₩5,447, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Upcoming Dividend • Dec 20Upcoming dividend of ₩490 per share at 12% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 12%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).Buying Opportunity • Dec 29Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩10,749, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 20%.株主還元A377740KR BiotechsKR 市場7D-0.3%-5.2%-8.7%1Y-11.3%-12.6%101.6%株主還元を見る業界別リターン: A377740過去 1 年間で-12.6 % の収益を上げたKR Biotechs業界を上回りました。リターン対市場: A377740は、過去 1 年間で101.6 % のリターンを上げたKR市場を下回りました。価格変動Is A377740's price volatile compared to industry and market?A377740 volatilityA377740 Average Weekly Movement3.9%Biotechs Industry Average Movement11.3%Market Average Movement9.4%10% most volatile stocks in KR Market16.7%10% least volatile stocks in KR Market4.9%安定した株価: A377740 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A377740の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2003n/aByungKi Chowww.bionote.co.krバイオノート社は韓国で動物用体外診断用医薬品を製造・販売している。蛍光免疫測定法、分子診断学、臨床生化学、迅速免疫測定法、酵素結合免疫吸着測定法などの動物用診断薬を提供。また、ヒト用迅速免疫測定、ヒト用中間体、バイオコンテンツ試薬などのバイオコンテンツ製品も提供している。また、医療機器の製造・販売も行っている。バイオノート社は2003年に設立され、本社は韓国華城市にある。もっと見るBioNote, Inc. 基礎のまとめBioNote の収益と売上を時価総額と比較するとどうか。A377740 基礎統計学時価総額₩475.60b収益（TTM）-₩50.23b売上高(TTM)₩122.44b3.9xP/Sレシオ-9.5xPER（株価収益率A377740 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A377740 損益計算書（TTM）収益₩122.44b売上原価₩52.84b売上総利益₩69.60bその他の費用₩119.83b収益-₩50.23b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-496.35グロス・マージン56.84%純利益率-41.02%有利子負債／自己資本比率0%A377740 の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.3%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 19:07終値2026/07/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioNote, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Buy Or Sell Opportunity • May 13Now 23% overvaluedOver the last 90 days, the stock has fallen 14% to ₩5,010. The fair value is estimated to be ₩4,067, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Apr 10Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to ₩4,970. The fair value is estimated to be ₩4,134, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,110, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past three years.
Declared Dividend • Feb 28Dividend of ₩229 announcedShareholders will receive a dividend of ₩229. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but not adequately covered by cash flows (99% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 81% to shift the payout ratio to a potentially unsustainable range, which is more than the 27% EPS decline seen over the last 5 years.
お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2026BioNote, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Korea
お知らせ • Feb 21BioNote, Inc. to Report Fiscal Year 2025 Results on Feb 25, 2026BioNote, Inc. announced that they will report fiscal year 2025 results on Feb 25, 2026
Buy Or Sell Opportunity • May 13Now 23% overvaluedOver the last 90 days, the stock has fallen 14% to ₩5,010. The fair value is estimated to be ₩4,067, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Apr 10Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to ₩4,970. The fair value is estimated to be ₩4,134, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 42% over the last 3 years. Meanwhile, the company became loss making.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,110, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 24% over the past three years.
Declared Dividend • Feb 28Dividend of ₩229 announcedShareholders will receive a dividend of ₩229. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but not adequately covered by cash flows (99% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 81% to shift the payout ratio to a potentially unsustainable range, which is more than the 27% EPS decline seen over the last 5 years.
お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2026BioNote, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Korea
お知らせ • Feb 21BioNote, Inc. to Report Fiscal Year 2025 Results on Feb 25, 2026BioNote, Inc. announced that they will report fiscal year 2025 results on Feb 25, 2026
分析記事 • Nov 25BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings SuggestBioNote, Inc. ( KRX:377740 ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...
お知らせ • Oct 28BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450).BioNote, Inc. (KOSE:A377740) signed a stock transfer agreement to acquire an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) for KRW 21.9 billion on September 26, 2025. A cash consideration of KRW 21.88 billion valued at KRW 8532 per share will be paid by BioNote, Inc. As part of consideration, KRW 21.88 billion is paid towards common equity of CTCBIO Inc. The expected completion of the transaction is December 24, 2025. BioNote, Inc. (KOSE:A377740) completed the acquisition of an additional 10.6% stake in CTCBIO Inc. (KOSDAQ:A060590) from PharmaResearch Co., Ltd. (KOSDAQ:A214450) on October 27, 2025. On completion, BioNote, Inc. and PharmaResearch Co., Ltd. will own 23.04% and 10.61% stake respectively in CTCBIO Inc.
Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: ₩834 (vs ₩66.00 in 2Q 2024)Second quarter 2025 results: EPS: ₩834 (up from ₩66.00 in 2Q 2024). Revenue: ₩32.4b (up 23% from 2Q 2024). Net income: ₩84.5b (up ₩77.8b from 2Q 2024).
お知らせ • Jul 08BioNote, Inc. (KOSE:A377740) announces an Equity Buyback for KRW 5,000 million worth of its shares.BioNote, Inc. (KOSE:A377740) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with NH Investment & Securities. The purpose of the program is to stabilize stock price and improve shareholder value. The program will expire on January 27, 2026. As of July 7, 2025, the company had 694,802 shares in treasury within scope available for dividend and no shares under other acquisitions.
分析記事 • May 26BioNote's (KRX:377740) Performance Is Even Better Than Its Earnings SuggestEven though BioNote, Inc.'s ( KRX:377740 ) recent earnings release was robust, the market didn't seem to notice. Our...
Declared Dividend • Feb 27Dividend of ₩200 announcedDividend of ₩200 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st January 1970 Dividend yield will be 4.1%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (51% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 10% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Feb 27BioNote, Inc., Annual General Meeting, Mar 26, 2025BioNote, Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 30, samsung 1-ro 4-gil, gyeonggi-do, hwaseong South Korea
お知らせ • Feb 26BioNote, Inc. announces Annual dividendBioNote, Inc. announced Annual dividend of KRW 200.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.
分析記事 • Nov 24BioNote's (KRX:377740) Strong Earnings Are Of Good QualityDespite posting some strong earnings, the market for BioNote, Inc.'s ( KRX:377740 ) stock hasn't moved much. Our...
New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (117% cash payout ratio). Share price has been volatile over the past 3 months (9.1% average weekly change). Large one-off items impacting financial results.
分析記事 • Aug 16BioNote, Inc.'s (KRX:377740) 38% Price Boost Is Out Of Tune With EarningsThe BioNote, Inc. ( KRX:377740 ) share price has done very well over the last month, posting an excellent gain of 38...
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩5,740, the stock trades at a trailing P/E ratio of 30.6x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 18% over the past year.
お知らせ • Aug 02BioNote, Inc. (KOSE:A377740) announces an Equity Buyback for KRW 10,000 million worth of its shares.BioNote, Inc. (KOSE:A377740) announces a share repurchase program. Under the program, the company will repurchase up to KRW 10,000 million worth of its shares, pursuant to a contract with NH Investment & Securities. The purpose of the program is to stabilize stock price and improve shareholder value. The program will expire on February 3, 2025. As of August 1, 2024, the company had no shares in treasury within scope available for dividend and under other acquisitions.
分析記事 • May 25There May Be Some Bright Spots In BioNote's (KRX:377740) EarningsThe market for BioNote, Inc.'s ( KRX:377740 ) shares didn't move much after it posted weak earnings recently. We did...
Upcoming Dividend • Mar 21Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 17 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 11%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.5%).
Buy Or Sell Opportunity • Mar 07Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩4,355. The fair value is estimated to be ₩5,447, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Upcoming Dividend • Dec 20Upcoming dividend of ₩490 per share at 12% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 17 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 12%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (0.7%).
Buying Opportunity • Dec 29Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩10,749, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 20%.
